Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth E Sherman

Showing results (191-200 of 211) with videos related to

Pageof 22
Sort By:
Digestive Diseases and Sciences|August 31, 2019
Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis IndexKenneth E Sherman, Enass A Abdel-Hameed, Richard L Ehman, et al.
Annals of Internal Medicine|May 21, 2013
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trialMark S Sulkowski, Kenneth E Sherman, Douglas T Dieterich, et al.
Vaccine|December 20, 2017
Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infectionCarey L Shive, Chelsey J Judge, Brian Clagett, et al.
JAMA|July 2, 2025
HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine: The BEe-HIVe Trial End-of-Study ResultsKristen M Marks, Minhee Kang, Triin Umbleja, et al.
Plos One|October 10, 2022
Cocaine use associated gut permeability and microbial translocation in people living with HIV in the Miami Adult Study on HIV (MASH) cohortJacqueline Hernandez, Javier A Tamargo, Sabrina Sales Martinez, et al.
Alcoholism, Clinical and Experimental Research|January 25, 2022
A review of alcohol-pathogen interactions: New insights into combined disease pathomechanismsNatalia A Osna, Moses New-Aaron, Raghubendra S Dagur, et al.
JAMA|December 1, 2024
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical TrialKristen M Marks, Minhee Kang, Triin Umbleja, et al.
Scientific Reports|February 18, 2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infectionGary P Wang, Norah Terrault, Jacqueline D Reeves, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|September 4, 2012
Protective role of humoral immune responses during an outbreak of hepatitis E in EgyptMohamed T Shata, Enas A Daef, Maysaa E Zaki, et al.
Pageof 22

Showing results (191-200 of 211) with videos related to

Sort By:
Pageof 22
Digestive Diseases and Sciences|August 31, 2019
Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis IndexKenneth E Sherman, Enass A Abdel-Hameed, Richard L Ehman, et al.
Annals of Internal Medicine|May 21, 2013
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trialMark S Sulkowski, Kenneth E Sherman, Douglas T Dieterich, et al.
Vaccine|December 20, 2017
Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infectionCarey L Shive, Chelsey J Judge, Brian Clagett, et al.
JAMA|July 2, 2025
HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine: The BEe-HIVe Trial End-of-Study ResultsKristen M Marks, Minhee Kang, Triin Umbleja, et al.
Plos One|October 10, 2022
Cocaine use associated gut permeability and microbial translocation in people living with HIV in the Miami Adult Study on HIV (MASH) cohortJacqueline Hernandez, Javier A Tamargo, Sabrina Sales Martinez, et al.
Alcoholism, Clinical and Experimental Research|January 25, 2022
A review of alcohol-pathogen interactions: New insights into combined disease pathomechanismsNatalia A Osna, Moses New-Aaron, Raghubendra S Dagur, et al.
JAMA|December 1, 2024
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical TrialKristen M Marks, Minhee Kang, Triin Umbleja, et al.
Scientific Reports|February 18, 2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infectionGary P Wang, Norah Terrault, Jacqueline D Reeves, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|September 4, 2012
Protective role of humoral immune responses during an outbreak of hepatitis E in EgyptMohamed T Shata, Enas A Daef, Maysaa E Zaki, et al.
Pageof 22